253222-68-3Relevant articles and documents
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER
-
Page/Page column 37-38, (2009/07/03)
The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
CHEMICALLY MODIFIED POLYCATION POLYMER FOR SIRNA DELIVERY
-
Page/Page column 18, (2008/06/13)
The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.
Conjugates of the hydrophilic polymer and the molecules from boxwood extraction, and pharmaceutical compositions of the conjugates
-
Page/Page column 4, (2008/06/13)
The present invention relates to a group of conjugates of the hydrophilic polymers and the molecules from boxwood extraction. PEGylation process or the process alike was used to generate the conjugates, which have increased water solubility and prolonged the circulation half-life in the body.